SAN FRANCISCO (360Dx) – Accelerate Diagnostics expects to begin clinical trials early in the third quarter of this year or before then in preparation for a submission for clearance to the US Food and Drug Administration for the second test in its pipeline, Lawrence Mehren, the firm's president and CEO, said during a presentation at the 36th annual JP Morgan Healthcare Conference on Wednesday.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.